ClinicalTrials.gg
Not yet recruitingNCT07482215Updated Mar 19, 2026

Prevalence and Molecular Identification of Human Schistosomiasis

An observational study in Schistosomiasis, sponsored by Assiut University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
359
Sex
All
01

Study summary

Schistosomiasis remains one of the most important parasitic diseases of public health concern, particularly in developing countries including Egypt. It is caused by a trematode worm (blood flukes) of the genus Schistosoma

Read the detailed description

Schistosomiasis has been diagnosed in Egypt since pharaonic times (3200 B.C.) by recovering Schistosome eggs and antigens in ancient mummies.In Egypt, Schistosoma mansoni and Schistosoma haematobium have historically been highly endemic, with widespread distribution along the Nile Delta and Valley.(4) Schistosoma haematobium is responsible for urogenital schistosomiasis, with hematuria as its primary manifestation, while Schistosoma mansoni, the prevalent species in Egypt, is causing intestinal schistosomiasis with liver-related sequelae

02

Conditions studied

  • Schistosomiasis

Browse trials for

03

In context

Schistosomiasis

79 studies on the registry are indexed under Schistosomiasis; 14 are open to participants now.

This study's planned enrollment of 359 is below the median of 532 across 25 observational studies indexed under Schistosomiasis.

Browse Schistosomiasis studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Probability sample

Study population

All participants presented in Assiut Governorate hospitals

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged ≥ 5 years of both sexes attending Assiut Governorate hospitals during the study period.
  • Patients clinically suspected of having schistosomiasis (urinary and/or intestinal) or referred for parasitological examination.
  • Individuals (or guardians, in case of minors) who provide written .
  • Patients willing to provide the required biological samples (urine and/or stool).

Exclusion criteria

Exclusion Criteria:

  • Patients Received praziquantel within the last 3 months before sample collection
  • Patients with incomplete clinical or epidemiological data.
  • Patients refusing participation or sample collection.
  • Improperly collected, contaminated, or insufficient samples.
  • Patients suffering from severe comorbid conditions that may interfere with the interpretation of results (e.g., advanced hepatic or renal failure).
  • children with congenital urinary or intestinal anomalies.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
359 participants (estimated)
Patient registry
No

Groups and cohorts

  • Schistosoma haematobium

    Urine filtration technique (10 ml urine) for diagnosis

    Diagnostic Test: Molecular phylogenetic and haplotype analysis

  • Schistosoma mansoni

    Direct wet mount and Kato-Katz thick smear technique (stool) for diagnosis

    Diagnostic Test: Molecular phylogenetic and haplotype analysis

Interventions

  • Diagnostic testMolecular phylogenetic and haplotype analysis

    DNA Sequencing and cox1 Gene Analysis of Schistosoma Isolates

06

What researchers measure

Primary outcomes

  1. prevalence of human schistosomiasis in the study participants

    using conventional microscopic examination

    Time frame: 24 hours

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07482215
Lead sponsor
Assiut University
Responsible party
Intesar Heshmat Yousef (Principial investigator, Assiut University) — Principal investigator
First posted
Mar 19, 2026
Start date
May 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion